Plunkett Research Online: CASI Pharmaceuticals Inc

CASI PHARMACEUTICALS INC (CASI:NAS) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing innovative therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before a.....



CASI Pharmaceuticals Inc
Ticker: CASI
Exchange: NAS
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 240 864-2600
Fax: 240 864-2601
Address: 9620 Medical Center Drive
Suite 300
Rockville, MD 20850 United States

Map
Types Of Business
Industry Ranks

Industry NAICS code:

Drugs-Angiogenesis
Biopharmaceuticals
Drug Development
Drug Commercialization
Clinical Trials
Contacts Description
Wei-Wu HeCEO/Chairman of the Board/Director
Wei ZhangCFO/President
See More
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing innovative therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before a.....See More See More

Auditor: KPMG Huazhen
Legal Advisor:
$USD, In whole numbers,
except marked * or %
202220212020201920182017
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and Affiliates Top Salaries
EVOMELA
CD19 CAR-T
BI-1206
CB-5339
CID-103
NameTitleSalary (US$)Bonus (US$)
Other Thoughts Corporate Culture

Apparent Female Officers or Directors: